

PROJECT SCARLETT - November 2025

An opportunity to launch AI-powered patented eyecare device to the medical technology market

Opportunity

- Innovative medical technology business seeking strategic options to facilitate its market entry
- Opportunity to unlock value in the medical and veterinary technology sectors and lead the commercialisation of the award-winning advanced eyecare device

Key Highlights

- Established in 2011 with a mission to eradicate preventable blindness with early symptom detection
- The Company has developed a revolutionary retinal imaging device which presents a next-generation technology-enabled eyecare solution
- The product is a high-resolution imaging system advancing eye care diagnostics with HD video and still images
- Integrated AI for rapid image analysis to streamline and enhance optometry services
- The product is CE marked, and FDA cleared, therefore can be sold in the UK, US and Europe
- Lightweight, handheld and portable device with a cutting-edge design and custom-built software, ideally suited to clinical and remote use
- The product is market-ready and patented in Europe and the US, protecting the Company's valuable IP
- The Company has attracted significant investment to date of c.£7m and is now seeking a funding solution alongside existing investors to launch to market

Expressions of Interest

- Interested parties will be required to sign a (NDA) before further information is provided.
- Indicative offers are required by 4pm Wednesday, 10 December 2025

Key Statistics**£7m**

Invested to date

2

Live patent families

£11m

FY30 forecast EBITDA

Financial Overview

£000					
YE 31 Dec	FY26	FY27	FY28	FY29	FY30
Revenue	544	2291	5070	12866	21089
Cost of Sales	(205)	(587)	(1362)	(2907)	(4552)
Gross Profit	339	1705	3708	9959	16537
Overheads	(2978)	(4452)	(4994)	(5042)	(6030)
EBITDA	(2638)	(2748)	(1286)	4917	10507
Gross Profit %	62%	74%	73%	77%	78%

For Further Information

Further information is available upon completion and return of a Non-Disclosure Agreement (NDA), which is available on request. Enquires should be directed in the first instance to:

Name

E. richard.temple@eddisons.com

Important Notice

The information above has been supplied by our Client and should not be relied upon as statements or representations of fact or warranties of any kind. Eddisons, its Directors and employees shall not be responsible for any error, omission or misstatement. Neither we nor our Client accept any responsibility whatsoever in respect of these particulars, which are simply offered as a general indication to parties who may be interested. Any notice of sale does not constitute an offer or contract.